文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺IMRT联合直肠/前列腺水凝胶间隔物后的性生活质量:3期试验二次分析

Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial.
PubMed 文献 · Pract Radiat Oncol · 2017-07-19

本文为一项3期试验的二次分析,共纳入222例接受前列腺IMRT的患者,中位随访37个月,评估水凝胶间隔物对阴茎球剂量及性生活质量的影响。结果显示水凝胶可降低阴茎球平均剂量、最大剂量及接受10-30 Gy的百分比(均P<.05),并与15个月时足够性交的勃起功能间接相关(P=.03)。在基线性生活质量充足(EPIC>60)的亚组中,3年时水凝胶组性功能更优(P=.03),勃起足够性交比例更高(66.7% vs 37.5%,P=.046)。

要点

  • 水凝胶间隔物降低阴茎球平均剂量、最大剂量及V10-30Gy(均P<.05)。
  • 基线EPIC>60亚组中,3年时水凝胶组性功能更优(P=.03)。
  • 3年时水凝胶组勃起足够性交比例更高(66.7% vs 37.5%,P=.046)。

核心结论

  • 水凝胶间隔物降低阴茎球剂量,并与患者报告的勃起功能改善相关。

研究设计与样本

  • 3期试验的二次分析,共222例男性患者,中位随访37个月。

主要发现

  • 水凝胶降低阴茎球平均剂量、最大剂量及接受10-30 Gy的百分比(均P<.05)。
  • 阴茎球平均剂量与15个月时足够性交的勃起功能间接相关(P=.03)。
  • 基线EPIC低(53±24),两组无差异(P>.1);41%(88/222)基线性生活质量充足(EPIC>60,均值77±8.3)。
  • 基线充足亚组3年时水凝胶组性功能更优(P=.03),性困扰差异较小(P=.1),EPIC汇总评分水凝胶组58±24.1 vs 对照组45±24.4,达MID但无统计学意义(P=.07)。
  • 3年时基线有勃起功能且用水凝胶者勃起足够性交比例更高(66.7% vs 37.5%,P=.046),性域13项中7项评分更高(均P<.05)。

临床怎么用

  • 在前列腺IMRT中考虑使用直肠/前列腺水凝胶间隔物以降低阴茎球剂量并可能改善性生活质量。

局限性

  • 为3期试验的二次分析,部分性生活质量比较未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously reported the results of a phase 3 trial evaluating a prostate/rectal hydrogel spacer during prostate intensity modulated radiation therapy, which resulted in decreased rectal dose and toxicity and less decline in bowel quality of life (QOL). A secondary analysis was performed to correlate penile bulb dose and sexual QOL. METHODS AND MATERIALS: Sexual QOL was measured with the Expanded Prostate Cancer Index Composite (EPIC) by mean scores, the proportion of patients with a minimal clinically important difference (MID), and analyses of the different items composing the sexual domain. RESULTS: A total of 222 men enrolled with median follow-up of 37 months. Hydrogel reduced penile bulb mean dose, maximum dose, and percentage of penile bulb receiving 10 to 30 Gy (all P < .05) with mean dose indirectly correlated with erections sufficient for intercourse at 15 months (P = .03). Baseline EPIC was low (53 [standard deviation ± 24]) with no difference between arms (P > .1). A total of 41% (88/222) of men had adequate baseline sexual QOL (EPIC >60 (mean, 77 [± 8.3]). This subgroup at 3 years had better sexual function (P = .03) with a spacer with a smaller difference in sexual bother (P = .1), which resulted in a higher EPIC summary on the spacer arm (58 [±24.1] vs control 45 [± 24.4]) meeting threshold for MID without statistical significance (P = .07). There were statistically nonsignificant differences favoring spacer for the proportion of men with MID and 2× MID declines in sexual QOL with 53% vs 75% having an 11-point decline (P = .064) and 41% vs 60% with a 22-point decline (P = .11). At 3 years, more men potent at baseline and treated with spacer had "erections sufficient for intercourse" (control 37.5% vs spacer 66.7%, P = .046) as well as statistically higher scores on 7 of 13 items in the sexual domain (all P < .05). CONCLUSIONS: The use of a hydrogel spacer decreased dose to the penile bulb, which was associated with improved erectile function compared with the control group based on patient-reported sexual QOL.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hamstra DA, Mariados N, Sylvester J, et al. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Pract Radiat Oncol. 2017. PMID: 28951089. doi:10.1016/j.prro.2017.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。